Skip to main
MANE

VeraDermics Inc (MANE) Stock Forecast & Price Target

VeraDermics Inc (MANE) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Veradermics is a clinical-stage biopharmaceutical company focused on addressing prevalent and challenging dermatological conditions. The company's drug VDPHL01 for hair loss has shown promising results and the market for hair loss treatments is projected to grow until 2035. Additionally, the company has a strong commercial strategy and experienced leadership, making it a potentially profitable investment opportunity.

Bears say

Veradermics is a clinical-stage biopharmaceutical company focusing on developing therapeutics for aesthetical and dermatological conditions, with a primary focus in the single segment of allocating resources, assessing performance, and making operating decisions. However, the company's negative outlook can be attributed to several factors, including the highly fragmented and under-innovated PHL treatment landscape, limited clinical benefits and potential safety concerns of current treatment options, and the lack of a convenient, non-hormonal oral treatment for PHL. Additionally, while Veradermics' lead product, VDPHL01, has shown promising results in clinical trials, its potential market share and revenue may still be limited due to the company's lack of experience in commercialization and potential competition in the PHL market.

VeraDermics Inc (MANE) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of VeraDermics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About VeraDermics Inc (MANE) Forecast

Analysts have given VeraDermics Inc (MANE) a Strong Buy based on their latest research and market trends.

According to 6 analysts, VeraDermics Inc (MANE) has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $150.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $150.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

VeraDermics Inc (MANE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.